Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.52 USD
+0.01 (2.94%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.52 0.00 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SGMO 0.52 +0.01(2.94%)
Will SGMO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
Other News for SGMO
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Biotech Roundtable: Who will bring the next CRISPR drug to market?
12 Health Care Stocks Moving In Friday's Intraday Session
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall